Tumor heterogeneity in response to therapy and its association with outcome in patients with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Liu, Junjia [1 ]
Xie, Hao [2 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] H Lee Moffitt Canc Ctr Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5255
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictors of treatment attrition in patients with metastatic colorectal cancer (mCRC).
    Bahrabadi, Arvin
    Ruan, Jenny
    Gresham, Gillian
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Survival for patients with resectable lung metastatic colorectal cancer (mCRC).
    Price, Timothy Jay
    Tomita, Yoko
    Beeke, Carol
    Padbury, Robert
    Townsend, Amanda Rose
    Maddern, Guy
    Roy, Amitesh
    Roder, David
    Karapetis, Christos Stelios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [23] Preliminary results of the association of weekly irinotecan and capecitabine as first line therapy for metastatic colorectal cancer (MCRC)
    Kattan, Joseph
    Farhat, Fadi
    Ghosn, Marwan
    Nasr, Fadi
    Mokaddem, Walid
    Tueini, Elias
    Dagher, Joya
    Younes, Fariha
    Chahine, Georges
    ANNALS OF ONCOLOGY, 2004, 15 : 100 - 100
  • [24] Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer
    Joung, Je-Gun
    Oh, Bo Young
    Hong, Hye Kyung
    Al-Khalidi, Hisham
    Al-Alem, Faisal
    Lee, Hae-Ock
    Bae, Joon Seol
    Kim, Jinho
    Cha, Hong-Ui
    Alotaibi, Maram
    Cho, Yong Beom
    Hassanain, Mazen
    Park, Woong-Yang
    Lee, Woo Yong
    CLINICAL CANCER RESEARCH, 2017, 23 (23) : 7209 - 7216
  • [25] ASSOCIATION BETWEEN CPG ISLAND METHYLATOR PHENOTYPE (CIMP) AND TREATMENT RESPONSE OF FOLFIRI WITH CETUXIMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)
    Kim, S. H.
    Park, K. H.
    Shin, S. J.
    Lee, K. Y.
    Kim, T. I.
    Kim, N. K.
    Rha, S. Y.
    Roh, J. K.
    Ahn, J. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 41 - 42
  • [26] Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy
    Akinwande, Olaguoke
    Philips, Prejesh
    Scoggins, Charles R.
    Kelly, Lawrence
    Tatum, Cliff
    Hahl, Mike
    McMasters, Kelly M.
    Martin, Robert C. G.
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (04) : 443 - 448
  • [27] Primary Tumor Location Found to Impact Prognosis and Response to Therapy in Patients With Metastatic Colorectal Cancer
    Barton, Mary Kay
    CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (04) : 259 - 260
  • [28] Stereotactic body radiation therapy (SBRT) in metastatic colorectal cancer (mCRC)
    Mireia, G. R.
    Marina, M. A.
    Ana, H. M.
    Maria Jose, S. A.
    Miriam, L. D. M.
    Silvia, C. F.
    Amaya, F. D.
    Alejandro, H. P.
    Jose, L. T.
    Carlos, C. H.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S792 - S793
  • [29] NK cells infiltrate in primary tumor influences response to cetuximab (CTX) in first-line therapy of metastatic colorectal cancer (mCRC)
    Marechal, R.
    Nagy, N.
    Verrellen, A.
    Larsimont, D.
    Hendlisz, A.
    Demols, A.
    Demetter, P.
    Van Laethem, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC).
    Sawada, Kentaro
    Okamoto, Wataru
    Nakamura, Yoshiaki
    Yamanaka, Takeharu
    Yuki, Satoshi
    Yoshino, Takayuki
    Komatsu, Yoshito
    Sakamoto, Naoya
    Fujii, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345